Artemis Medicare Services Limited has informed the Exchange regarding Change in Auditors of the company.
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Artemis Medicare Services Limited reported FY25 standalone revenue from operations of ₹913.26 crore, up about 8% from ₹845.23 crore in FY24. Net profit jumped roughly 70% to ₹83.46 crore (vs ₹49.15 crore), with profit before tax at ₹109.25 crore. The board recommended a final dividend of ₹0.45 per share (45% on face value of ₹1) for FY25. On the board, Mr. Sunam Sarkar was appointed as an Additional Non-Executive Non-Independent Director, Dr. Nirmal Kumar Ganguly resigned citing personal reasons, and Ms. Deepa Gopalan Wadhwa's term as Independent Director ends May 21, 2025. The board also appointed M/s. DMK Associates as Secretarial Auditor for five years (FY26–FY30). Statutory auditor T R Chadha & Co LLP issued an unmodified opinion.
Strong FY25 earnings growth and a healthy 45% dividend are positive for shareholders. Director changes appear routine rather than governance red flags, and the earlier ₹330 crore CCD issuance to IFC remains in place, supporting the company's expansion plans. Net cash position and rising profits may lift sentiment around the stock.